Companies · Pharmaceuticals

PCAS Patient Care Automation Services Inc.

TORONTO · Pharmaceuticals

Diligence memoA one-page analyst read on PCAS Patient Care Automation Services Inc. — recommendation, valuation, rhythm, risks.
$77.0M
Total raised · real
2
Rounds
10.0×
Latest step-up
Top 13%
Sector rank · raised
Series C
Latest stage · inferred · Fri Dec 24 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

PCAS Patient Care Automation Services Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.37× the median modeled value of Series C Pharmaceuticals companies in 2010–2012 (12 peers) — value vs value, same stage and era.
  • Within the normal band (137% of peer median) for its niche.
Dormant
  • Last raise 15.5 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

PCAS Patient Care Automation Services Inc. is one of 1610 Pharmaceuticals companies tracked from TORONTO. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries A · 2010-12-24 Raised $7.0M (real) Modeled valuation $217M (est)$7.0M$217MSeries A2010Series C · 2010-12-24 Raised $70M (real) Modeled valuation $2.5B (est)$70M$2.5BSeries C2010+$70MCumulative $77M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$7.0M · 2010
Series C$70.0M · 2010no Series B on file

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$2.5B
Base estimate est.
$227.4M
Conservative case
$6.5B
Upside case
$466.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $216.8M · 2010-12-242010Series C · modeled $2.5B · 2010-12-242010
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
66%
Survival probability
49% low · 76% high
1.42×/yr
Annual markup
1.62×/yr upside case
6.0 yr
Elapsed time used
15.5 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
15.5 yr
On record since
2010
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 9.5× above median
This company$77.0M
Sector median$8.1M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.5× above median
This company$70.0M
Sector median$46.7M
Modeled value — vs sector median (estimate, all stages) 32× above median
This company$2.5B
Sector median$76.1M

Raised more than 88% of sector peers (real $). Modeled value above 96% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 12.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Acadia Pharmaceuticals Inc · Series C Raised $107.5M · modeled $3.0B (est)Agios Pharmaceuticals Inc · Series C Raised $86.8M · modeled $2.7B (est)Merrimack Pharmaceuticals Inc · Series C Raised $77.0M · modeled $2.7B (est)China Medicine Corp · Series C Raised $69.6M · modeled $2.4B (est)Brickell Bay Acquisition Corp. · Series C Raised $52.4M · modeled $1.8B (est)Achillion Pharmaceuticals Inc · Series C Raised $50.1M · modeled $1.8B (est)Aragon Pharmaceuticals, Inc. · Series C Raised $141.5M · modeled $1.8B (est)Zogenix Inc · Series C Raised $131.2M · modeled $526.4M (est)Global Pharm Holdings Group, Inc. · Series C Raised $66.0M · modeled $350.9M (est)Portola Pharmaceuticals Inc · Series C Raised $158.1M · modeled $315.8M (est)Aveo Pharmaceuticals Inc · Series C Raised $98.2M · modeled $263.2M (est)PCAS Patient Care Automation Services Inc. (this company) Raised $77.0M · modeled $2.5B (est)PCAS Patient Care Automation Services Inc.
CompanyStageRaised · realValue · estvs peer med.
Acadia Pharmaceuticals IncSeries C$107.5M$3.0B1.69×
Agios Pharmaceuticals IncSeries C$86.8M$2.7B1.52×
Merrimack Pharmaceuticals IncSeries C$77.0M$2.7B1.50×
PCAS Patient Care Automation Services Inc. this companySeries C$77.0M$2.5B1.37×
China Medicine CorpSeries C$69.6M$2.4B1.36×
Brickell Bay Acquisition Corp.Series C$52.4M$1.8B1.02×
Achillion Pharmaceuticals IncSeries C$50.1M$1.8B0.98×
Aragon Pharmaceuticals, Inc.Series C$141.5M$1.8B0.98×
Zogenix IncSeries C$131.2M$526.4M0.29×
Global Pharm Holdings Group, Inc.Series C$66.0M$350.9M0.20×
Portola Pharmaceuticals IncSeries C$158.1M$315.8M0.18×
Aveo Pharmaceuticals IncSeries C$98.2M$263.2M0.15×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$7.0M2010-12-24$31.8M$216.8M90%
Series C$70.0M2010-12-24$466.7M$2.5B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$7.0M2010-12-24
    • First recorded raise — entered as Series A.
  2. Series C$70.0M2010-12-24
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 10.0× larger than the prior — scaling up.
Intelligence
Modeled next raise
$210.0M
Modeled next size est.range $136.5M$336.0M
10.0×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Anthony Kym2010-12
Dante Morra2010-12
David Archibald2010-12
David Gibbins2010-12
Don Waugh2010-12
Jean Joubert2010-12
Peter Suma2010-12
Phil Richardson2010-12
Wendy Graham2010-12
Registry & provenance

PCAS Patient Care Automation Services Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1509596
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Merrimack Pharmaceuticals IncPharmaceuticalsSeries C$77.0M$2.7Bsame sector · same stage
Trevena IncPharmaceuticalsSeries C$77.5M$2.1Bsame sector · same stage
MEI Pharma, Inc.PharmaceuticalsSeries C$76.1M$2.6Bsame sector · same stage
Tvardi Therapeutics, Inc.PharmaceuticalsSeries C$78.1M$1.8Bsame sector · same stage
Aerovate Therapeutics, Inc.PharmaceuticalsSeries C$78.3M$2.6Bsame sector · same stage
Expansion Therapeutics, Inc.PharmaceuticalsSeries C$78.3M$1.1Bsame sector · same stage
Avilar Therapeutics, Inc.PharmaceuticalsSeries C$75.3M$2.3Bsame sector · same stage
Complexa Inc.PharmaceuticalsSeries C$78.9M$386.0Msame sector · same stage
Frequently asked
How much funding has PCAS Patient Care Automation Services Inc. raised?
PCAS Patient Care Automation Services Inc. has raised approximately $77.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is PCAS Patient Care Automation Services Inc.'s estimated valuation?
Provath's modeled valuation for PCAS Patient Care Automation Services Inc. is approximately $2.5B (modeled range $227.4M–$6.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is PCAS Patient Care Automation Services Inc. at?
PCAS Patient Care Automation Services Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Dec 24.
What does PCAS Patient Care Automation Services Inc. do and where is it based?
PCAS Patient Care Automation Services Inc. operates in the Pharmaceuticals sector, based in TORONTO.
Explore related

See where PCAS Patient Care Automation Services Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at PCAS Patient Care Automation Services Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.